Overview

Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5

Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to investigate the efficacy of lenalidomide in high risk MDS or AML with chromosome 5 aberrations.
Phase:
Phase 2
Details
Lead Sponsor:
Nordic MDS Group
Treatments:
Lenalidomide
Thalidomide